Saltar al contenido
Merck
  • Strict glycaemic control improves skin microcirculation in patients with type 2 diabetes: a report from the Diabetes mellitus And Diastolic Dysfunction (DADD) study.

Strict glycaemic control improves skin microcirculation in patients with type 2 diabetes: a report from the Diabetes mellitus And Diastolic Dysfunction (DADD) study.

Diabetes & vascular disease research (2012-03-02)
Christina Jarnert, Majid Kalani, Lars Rydén, Felix Böhm
RESUMEN

Microcirculatory and endothelial dysfunction are signs of cardiovascular engagement in patients with type 2 diabetes. This study tested whether glucose normalisation may reverse this. Thirty-nine T2DM patients (age 61±7 years, 58% females) with signs of mild diastolic dysfunction were randomised to strict glucose control based on insulin (I-group; n=21) or oral agents (O-group; n=18) for four months. Skin microcirculation was studied with laser Doppler fluxmetry and endothelial function with brachial artery flow-mediated dilatation. Glucose control improved (reduction of HbA(1c) I-group = -0.5%; O-group -0.7%; p=0.69). Microcirculation improved in the entire group (n=39) determined by foot laser Doppler fluxmetry (32.2±13.6 vs. 35.3±13.1 perfusion units; p<0.001) and laser Doppler fluxmetry following heating (68.8±34.0 vs. 69.3±25.1 PU; p=0.007). Improvement was more consistent with oral agents than insulin. Endothelial function expressed as flow-mediated dilatation decreased in the I-group (6.0±2.2 to 4.7±3.0%; p=0.037) but remained unchanged in the O-group (4.8±2.3 to 5.0±3.7%; n.s.). Glycaemic normalisation improved skin microcirculation but not endothelial function in patients with type 2 diabetes with mild cardiovascular engagement.

MATERIALES
Número de producto
Marca
Descripción del producto

Sigma-Aldrich
Repaglinide, ≥98% (HPLC), solid
En este momento no podemos mostrarle ni los precios ni la disponibilidad
Repaglinide, European Pharmacopoeia (EP) Reference Standard
En este momento no podemos mostrarle ni los precios ni la disponibilidad
Repaglinide for system suitability, European Pharmacopoeia (EP) Reference Standard
En este momento no podemos mostrarle ni los precios ni la disponibilidad